Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Bioshares Biotech Summit 2025
20 slides from Argenica Therapeutics's conference presentation, August 2025
Slide 1: Argenica Therapeutics Investor Presentation – Bioshares 2025
ARGENICA THERAPEUTICS INVESTOR PRESENTATION ASX: AGN BIOSHARES 2025 MANAGING DIRECTOR PRESENTATION 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: The Therapeutic Opportunity
NEUROPROTECTION ARGENICA THERAPEUTICS THE THERAPEUTIC OPPORTUNITY 3 www.argenica.com.au
Slide 4: Breakthrough Neuroprotective Therapy
BREAKTHROUGH NEUROPROTECTIVE THERAPY ABOUT ARG-007 MISSION Commercialise neuroprotective treatments that minimises brain damage and fosters recovery Cationic poly-arginine peptide following stroke & other neurological conditions ARGENICA THERAPEUTICS Multiple mechanisms of action working across mult
Slide 5: Our Lead Indications
OUR LEAD INDICATIONS DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 Efficacy Safety / Tox STROKE – ARG-007 Damage to the brain from interruption of its blood supply MOD-SEVERE TBI – ARG-007 ARGENICA THERAPEUTICS Trauma to the head or body causes a loss of consciousness HIE – ARG-006 & 007 Hypoxic is
Slide 6: Key Company Metrics
KEY COMPANY METRICS $10.5M $87M +$5M CASH @ BANK 1 MARKET CAP2 NON-DILUTIVE GRANTS 3 ARGENICA THERAPEUTICS 128.1M 37% SHARES HELD BY TOP 20 100% SHARES ON ISSUE PATIENTS ENROLLED IN PHASE 2 1. Cash balance as @ 30 June 2025 6 2. Calculated with closing price on @29th July 2025 being $0.68 www.argeni
Slide 7: Ischaemic Stroke Trial Update
ARGENICA THERAPEUTICS ISCHAEMIC STROKE TRIAL UPDATE 7 www.argenica.com.au
Slide 8: So Why Are We Targeting Stroke First?
SO WHY ARE WE TARGETING STROKE FIRST? INCIDENCE SOCIETAL IMPLICATIONS THE IMPORTANCE OF TIME ARGENICA THERAPEUTICS 45 SECONDS ONLY 10% 1.9 MILLION How often someone will recover almost brain cells are attacked each suffers an ischaemic completely, due to the extent minute during a stroke3 stroke in
Slide 9: Encouraging Stroke Results to Date
ENCOURAGING STROKE RESULTS TO DATE SUCCESSFUL PHASE 28 Days 1 (HUMAN after stroke in STUDY) PRECLINICAL & CLINICAL DATA preclinical model4 100% INDUCED Reduction in brain 90% STROKE cell death can make a significant difference SAFE TO 80% to patients’ outcome. ADMINISTER It could mean the IN THE FIE
Slide 10: Phase 2 Trial Design in Acute Ischaemic Stroke
PHASE 2 TRIAL DESIGN IN ACUTE ISCHAEMIC STROKE PATIENT HAS A PATIENT IN ARRIVES AT DIAGNOSE REHAB STROKE AMBULANCE HOSPITAL STROKE TYPE THROMBECTOMY BEGINS ARGENICA THERAPEUTICS Initial screening of Administration of Endpoints patients to meet inclusion 0.3mg/kg ARG-007 or PRIMARY: Mortality rate an
Slide 11: Example of What Phase 2 Trial Hopes to Achieve
EXAMPLE OF WHAT PHASE 2 TRIAL HOPES TO ACHIEVE: REDUCING INFARCT VOLUME (i.e. BRAIN DEATH) FOLLOWING STROKE & THROMBECTOMY Infarct core: permanent brain cell death (i.e. cannot be saved) Vulnerable Penumbra: Surrounding tissue that ARGENICA THERAPEUTICS is vulnerable to dying (i.e. still alive, but
Slide 12: Actual Patient Recruitment
PHASE 2 CLINICAL TRIAL IN STROKE 92 patients dosed at 8 Australian hospitals ACTUAL PATIENT RECRUITMENT Exceptional recruitment rate due to ease of 100 use of ARG-007 administration in acute 90 emergency setting ARGENICA THERAPEUTICS 80 70 Easy consent for patients due to clinician Patients Dosed 60
Slide 13: What Does a Reduction in Infarct Mean for Patients?
WHAT DOES A REDUCTION IN INFARCT MEAN FOR PATIENTS? Reducing infarct volume after an ischemic stroke is a crucial measure because data suggests it is the strongest predictor of better outcomes, including improved neurological function, independence, and lower mortality.¹ mRS Scale (i.e. a measure of
Slide 14: Clinically Meaningful Final Infarct Volume Reductions
HOW MUCH BRAIN DO YOU NEED TO SAVE? CLINICALLY MEANINGFUL FINAL INFARCT VOLUME REDUCTIONS • A 1.6% decrease in infarct volume (decrease in brain cell 100% 1.6% death) is the minimum amount of decrease deemed to INFARCT VOLUME REDUCTION (%) 90% Reduction be clinically important1. This decrease, on av
Slide 15: Post Phase 2 Strategy and Commercial Opportunities
POST PHASE 2 STRATEGY ARGENICA THERAPEUTICS AND COMMMERCIAL OPPORTUNITIES 15 www.argenica.com.au
Slide 16: The Stroke Opportunity
THE STROKE OPPORTUNITY Category Australia United States Number of strokes per year ~45,000 annually1 ~795,000 annually2 Cost of stroke to healthcare USD$71.55 billion in 2012 AUD$5.5 billion expected to increase to system per year in healthcare costs in 20231 USD$184.13 billion by 20303 ARGENICA THE
Slide 17: Post Phase 2 Strategy
POST PHASE 2 STRATEGY LICENSING OR PARTNERING: If the Phase 2 trial shows promising results, Argenica may license ARG-007 for stroke to a larger pharmaceutical group that has the global channels to commercialise in acute ischaemic stroke. OR… ARGENICA THERAPEUTICS CREATE GREATER MERGER & ACQUISITION
Slide 18: Neuro Deals on the Rise
NEURO DEALS ON THE RISE ARGENICA THERAPEUTICS 18 www.argenica.com.au
Slide 19: Near-Term Catalysts and Investment Highlights
3# NEAR-TERM CATALYSTS Phase 2 acute ischaemic stroke trial results imminent. Further regulatory and preclinical INVESTMENT milestones in the next 12 months. HIGHLIGHTS ARGENICA THERAPEUTICS 1# SOLVING LARGE UNMET NEEDS 2# Nervous system disorders are the SIGNIFICANT PRE- 4# biggest cause of poor he
Slide 20: Argenica Therapeutics
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 20 www.argenica.com.au
Argenica Therapeutics — Bioshares Biotech Summit 2025 on 6ix